Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London

PISCATAWAY, N.J., Sept. 25, 2025 /PRNewswire/ -- Cell and gene therapies (CGT) are advancing rapidly and are reshaping the future of medicine. From CRISPR-based genome editing to new applications of in vivo and ex vivo cell therapies, scientific breakthroughs are increasingly moving from the laboratory into clinical practice. At the same time, global investment and innovation in the field are accelerating, positioning CGT as one of the fastest-growing areas in life sciences.

One of the greatest challenges for the industry lies in translating these advances into lasting patient benefits and sustainable clinical impact. To address the opportunities and challenges of this evolving landscape, the GenScript Biotech Global Forum London 2025 will take place on November 20th, 2025, in London, United Kingdom, alongside the Jefferies London Healthcare Conference. Under the theme "THE NEXT ERA OF CGT IS HERE," the forum will bring together a Nobel Laureate, industry pioneers, and investors to explore how today's innovations can evolve into tomorrow's standards of care.

Registration is now officially open: RSVP here
(Use code GSGM2 to claim a complimentary ticket — limited to the first 20 registrants.)

Global Leaders Defining the Future of CGT

The keynote speakers will offer a panoramic view of the CGT landscape, capturing its most critical trends. Their diverse expertise across foundational science, clinical innovation, and regulatory strategy reflects the multidimensional progress shaping the future of CGT, and sets the stage for a forward-looking dialogue that unites research, industry, and patient care.

Dr. Craig Mello, Nobel Laureate in Physiology or Medicine (2006), University Chair in Molecular Medicine, co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School, is best known for his co-discovery of RNA interference (RNAi), a breakthrough that transformed genetic research and paved the way for RNA-based medicines. At the forum, Dr. Mello will reflect on how foundational science has evolved into real-world therapeutic innovation, and what lessons this holds for the next generation of CGT.

Dr. Carl June is the Richard W. Vague Professor in Immunotherapy and Director of the Center for Cellular Immunotherapies at the University of Pennsylvania. His pioneering work led to the first FDA-approved CAR-T therapy, ushering in a new era of cancer treatment. Dr. June will highlight the latest clinical advances in cellular immunotherapies and share his insight on the latest advances and future directions in cellular immunotherapies.

Dr. Miguel Forte, President and Board of Directors Chair of the International Society for Cell & Gene Therapy (ISCT), brings deep expertise in clinical development and regulatory strategy. With deep expertise in clinical translation and regulatory strategy, he will offer a global perspective on clinical translation, manufacturing (CMC) challenges, and regulatory pathways that will shape the scalability and accessibility of CGT.

Together, these keynote speakers will set the stage for a rich dialogue that bridges scientific discovery, industrial innovation, and clinical practice.

Exploring Diverse Pathways in Cell Therapy Innovation

Cell therapy continues to diversify rapidly, with autologous, allogeneic, and in vivo platforms each advancing along distinct paths. While these strategies share a common goal of transforming patient care, they present different challenges in scalability, safety, and cost. From solid tumor progress to novel technical breakthroughs and the transformative potential of AI, this session will spotlight the innovations and challenges shaping the next frontier of cell therapy.

Industry leaders such as Paula Río, Head of the Bone Marrow Aplasia Unit at CIEMAT/CIBERER/IIS-FJD, Marcello Maresca, Senior Director of Genome Engineering department, AstraZeneca, Paul Stoffels, Former CSO of J&J, Jonathan Esensten, Senior Advisor at Multiply Labs, and Stephen Hansen, Director of Biopharma Intelligence of BioCentury will participate in the panel discussions exploring the future of the CGT industry. Also, Dr. Ying Huang, CEO of Legend Biotech, the world's highest market value CAR-T company, will share the story of Legend's success.

Latest Progress and Future Outlook in Gene Therapy and mRNA

Gene therapy and mRNA technologies have moved from promise to practice, delivering clinical milestones in both rare diseases and broader indications. Yet important questions remain around durability, delivery, and long-term safety. This session will explore the state of the science and the opportunities that lie ahead as these modalities continue to evolve.

The panel will bring together leaders such as Julen Oyarzabal, CSO of Syngoi Technologies SL, Sergio Linares, Unit Head of RNA Science Automation from Sanofi, Luigi Calzolai, Scientific Officer at European Commission Joint Research Centre (JRC), Anna Cereseto, Head of Lab for Advanced Genome Editing Technologies, Robin Shattock, Chair in Mucosal Infection and Immunity at Imperial College London, Miroslav Gasparek, CEO and Co-founder of Sensible Biotechnologies. Together, they will discuss the latest technology platform, possible bottlenecks and future trends of gene therapy and mRNA.

Tackling CMC Challenges to Enable Broader Patient Access

As promising as CGT may be, the journey from laboratory discovery to patient treatment is often slowed by manufacturing hurdles. CMC remains critical pain points for the sector, particularly in achieving reproducibility, scalability, and regulatory compliance.

Industry leaders, including Jin Yin, CTO of CGT Technology Center at ProBio, Dima Al-hadithi, Founder and Director of Minaret Consulting Limited and RareGenix Consulting Limited, John Maher, Scientific Founder and CSO of Leucid Bio, Marten Hansen, Head of the Laboratory for Cell Therapy at the Sanquin Blood Supply Foundation, Peter Jones, Director of Pengwin Consultancy will share their experience in tackling manufacturing bottlenecks and driving advances that can make therapies more accessible. Their contributions will highlight both the current state of CMC innovation and the strategies needed to accelerate delivery of CGT to patients worldwide.

Innovation and Investment Shaping the CGT Landscape

The pace of scientific progress in CGT has been matched by strong interest from the investment community. However, turning breakthroughs into sustainable business models requires more than capital alone—it demands alignment between innovators and investors, as well as a clear understanding of the risks and opportunities ahead.

This panel discussion will feature perspectives from Michael Brinkman, Managing Director and Joint US Head of Biopharmaceuticals Investment Banking from Jefferies, Laura Stoppel, Partner on the Investment Team, RA Capital Management, Hongbo Lu, Founder and Managing Partner of NextBio Capital and Daniela Couto, General Partner from BioGeneration Ventures, Matthieu Coutet, Partner from Sofinnova Biovelocita Strategy, Michiel Broker, Managing Director and Global Head of Pharma from UBS alongside voices from the biotech sector, exploring how capital is being directed to support emerging companies and how innovation can be nurtured across the development lifecycle. The discussion will emphasize the interplay between scientific excellence and financial strategy in building a robust and sustainable CGT ecosystem.

Registration is Now Open

Registration is now officially open: RSVP here
(Use code GSGM2 to claim a complimentary ticket — limited to the first 20 registrants.)

Date: Thursday, 20 November 2025
Location: 116 Pall Mall, London, UK

SOURCE GenScript Biotech Corporation